Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
By G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, C. Gisselbrecht, A. Laurell, F. Offner, A. Strahs, A. Berkenblit and 5 more. Journal of Clinical Oncology, 2009
655 citations recorded by the source corpus.
Subfields: Dermatology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/8cb2c354b5d61db46c9fedd50381ae8c2b1daacd
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Michael N. Hall
- Don Benjamin
- M. Colombi
- C. Moroni
- C. Porta
- C. Paglino
- J. Sharman
- A. Mosca
Citations in the corpus
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. (2010, background): “Syk therefore appears also to also play a central role in mTOR activation; this is of particular relevance since targeting of mTOR signaling with temsirolimus has resulted in significant therapeutic activity in indolent lymphoma and mantle cell lymphoma.(30)”
- Rapamycin passes the torch: a new generation of mTOR inhibitors (2011, background): “Temsirolimus was also efficacious in treatment of refractory mantle cell lymphom”
- Targeting PI3K/Akt/mTOR Signaling in Cancer (2014, methodology): “9 months for the temsirolimus 175/75, 175/25 mg, and investigator’s choice groups, respectively (25).”